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Abstract
Background: The cause of premature cardiovascular disease (CVD) in inflammatory rheumatic diseases (IRDs) has
not been fully elucidated. As inflammation may play a role, we wanted to compare the occurrence and extent of
inflammatory cell infiltrates (ICIs), small vessel vasculitis, and the amount of adipose tissue and collagen in cardiac
biopsies taken from patients with coronary artery disease with and without IRDs.
Methods: From among the Feiring Heart Biopsy Study subjects, we selected patients undergoing coronary artery
bypass grafting from whom paraffin-embedded, formalin-fixed specimens from the right atrium were available. The
sample comprised 48 patients with IRD and 40 non-IRD patients. Hematoxylin and eosin staining was used to
examine the presence and location of ICIs and vasculitis, and Lendrum (Martius yellow, scarlet, and blue) staining
was carried out for collagen and adipose tissue.
Results: Epicardial ICIs were found in 27 (56 %) patients with IRD and 24 (60 %) non-IRD patients. There were no
significant differences between patients with IRD and non-IRD patients in the amount of cardiac ICIs and adipose tissue,
but patients with IRD had more collagen in the myocardium than non-IRD patients. Small vessel vasculitis was not
observed in any cardiac specimen. Patients with epicardial ICIs were, on average, 7 years younger than those without.
Conclusions: Our results do not support the notion that inflammation in cardiac peri-, epi-, and myocardium plays a
more important role in CVD of patients with IRD than non-IRD patients. The increased amount of collagen in the
myocardium of patients with IRD suggests differences in extracellular matrix composition and/or mass, which might play
a role in cardiac remodeling, and represent targets for novel therapies against heart failure.
Keywords: Inflammatory rheumatic diseases, Cardiovascular disease, Inflammation, Right atrium, Epicardium,
Myocardium, Endocardium, Extracellular matrix, Collagen, Epicardial adipose tissue
Background
Inflammatory rheumatic diseases (IRDs) are associated
with a wide range of cardiovascular complications, such
as atherosclerosis; vasculitis; cardiac valve failure; endo-,
myo-, and pericarditis; and heart failure [1–3]. The in-
creased cardiovascular morbidity strongly contributes to
the premature mortality in IRD [4]. However, the risk of
heart failure in rheumatoid arthritis (RA) seems to be
less dependent on coronary artery disease (CAD) and
traditional cardiovascular risk factors than that in the
general population [5]. Thus, not only the increased
prevalence of CAD but also other factors, such as systemic
inflammation and inflammation in the myocardium
and/or in small cardiac vessels, might play an important
role [6, 7]. Indeed, the high occurrence of myocardial in-
flammation in patients with autoimmune diseases and car-
diac symptoms has been described previously [6, 7].
* Correspondence: jacqueline.andersen@ntnu.no
1Department of Health, Technology and Society, Norwegian University of
Science and Technology (NTNU), Teknologiveien 22, 2815 Gjøvik, Norway
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Andersen et al. Arthritis Research & Therapy  (2016) 18:232 
DOI 10.1186/s13075-016-1136-5
Besides inflammation, other factors causing detrimental
cardiac remodeling also might be involved in the patho-
genesis of heart failure [8]. Cardiac remodeling is charac-
terized by pathologic changes in the morphology and
number of cardiomyocytes and in the composition of the
extracellular matrix (ECM), in particular collagen produc-
tion and degradation, resulting in adverse changes in the
shape, mass, and function of the heart [9, 10].
Interestingly, the amount and function of adipose tissue
in the cardiovascular system also might be of essential im-
portance for a well-functioning cardiovascular system. For
example, recent research suggests a strong link between
the volume of epicardial adipose tissue and the extent and
severity of CAD [11]. It is possible that the adipose tissue
in the cardiovascular system might promote inflammation
in adjacent tissue, such as in epicardial coronary arteries
and in the myocardium (e.g., by secretion of proinflamma-
tory cytokines and adipokines) [12, 13].
So far, there has been a lot of focus on the potential role
of systemic inflammation and its associated metabolic ef-
fects in the pathogenesis of premature cardiovascular dis-
ease (CVD) in IRD, while inflammatory and structural
changes in the cardiovascular system (in particular in the
heart) has attracted much less interest. Therefore, we
wanted to compare the occurrence and extent of in-
flammatory cell infiltrates (ICIs), the presence of small
vessel vasculitis, and the amount of collagen and adipose
tissue in all three layers of the heart (i.e., epicardium, myo-
cardium, and endocardium) in patients with CAD with
and without IRDs. Furthermore, we wanted to compare
the amount of ICIs in the heart and in skeletal muscle




We examined 48 patients with CAD with IRD and 40
patients with CAD without IRD who were subjects in the
Feiring Heart Biopsy Study (FHBS) from whom paraffin-
embedded, formalin-fixed specimens from the heart were
available [5]. In the FHBS, biopsies had been collected
from 70 patients with IRDs and 53 age- and sex-matched
patients without IRDs undergoing coronary artery by-
pass graft (CABG) surgery between May 2001 and July
2004 [14]. The exclusion criteria for both groups were
age <18 years or clinically significant infection or ma-
lignancy. In addition, for the CAD non-IRD group,
psoriasis was also included as an exclusion criterion
[14]. The IRD group in this study consisted of patients
with RA (n = 18), polymyalgia rheumatica (PMR) (n = 9),
psoriatic arthritis (PSA) (n = 8), ankylosing spondylitis
(AS) (n = 5), giant cell arteritis (GCA) (n = 3), systemic
lupus erythematosus (SLE) (n = 3), Reiter’s syndrome
(n = 1), and undifferentiated connective tissue disease
(n = 1).
Data collection
The patients were examined by biopsies taken during
CABG and via preoperative blood tests, interviews, phys-
ical examinations, and self-reported questionnaires [14].
Biopsy specimens and assessment
The cardiac specimens were taken in a standardized way
during CABG surgery from the edge of the cannulation
site of the right atrium. Specimens from the rectus ab-
dominis muscle were taken via the lower part of the rou-
tinely used midline sternal incision. The rectus abdominis
specimens were available from 28 patients without IRD
and 20 patients with IRD (11 RA, 3 PSA, 2 PMR, 2 GCA,
1 AS, and 1 undifferentiated connective tissue disease).
All specimens were fixed in 10 % buffered formalin,
embedded in paraffin, and cut into 3-μm sections. From
each patient, one section from both cardiac and skeletal
specimens was stained with hematoxylin and eosin and
examined for the presence and location of ICIs.
The number and extent of ICIs in the heart wall (for
each layer separately) and rectus abdominis were semi-
quantified. The number of ICIs per section was scored as
no infiltrates, one infiltrate, two or three infiltrates, and
more than three infiltrates. The size of the largest ICI in a
single section was scored as follows according to the
number of inflammatory cells observed: none, 1–49 cells,
50–99 cells, 100–199 cells, and ≥200 cells. The localization
of the infiltrates was classified as perivascular, interstitial, or
both perivascular and interstitial.
One section from each cardiac specimen was also stained
using Lendrum (Martius yellow, scarlet, and blue) stain to
detect collagen. The sections were deparaffinized and
brought to water. They were then incubated for 1 h at
60 °C in Bouin’s fixative and then rinsed in distilled
water, stained for 10 minutes in Weigert’s hematein,
and rinsed in distilled water and then in 96 % alcohol.
Martius yellow/phosphotungstic acid was used to stain
the slides for 5 minutes before the slides were rinsed in
distilled water and then stained for 14 minutes in bril-
liant crystal scarlet. Again the sections were rinsed in
distilled water, and then they were stained for 10 mi-
nutes in soluble blue. The sections were again rinsed in
distilled water, and then they were dehydrated through
alcohols and mounted in permanent mounting medium.
The amount of adipose tissue was scored as none, lit-
tle, medium, or pronounced, and the amount of collagen
was scored as little, moderate, or pronounced. Two in-
dependent investigators who were blinded to the clinical
data examined the histologic sections in random order
by light microscopy. When the interpretations were
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discordant, an additional reading was performed by a
third investigator to adjudicate the findings. The κ-value
for agreement between the first two investigators con-
cerning the occurrence of ICIs in the epicardial layer
was 0.905 (95 % CI 0.815–0.995) (p < 0.001).
Statistical analysis
Fisher’s mid-p test for dichotomous variables, independent
two-samples t test for normally distributed continuous
variables, and the Mann-Whitney U test for nonnormally
distributed continuous variables and ordered categorical
variables were used to identify differences between the
two groups. Logistic regression analyses were used to
assess the relationship between the presence of ICIs
and a set of covariates. Statistical analyses were performed
using IBM SPSS version 22 for Windows software (IBM,
Armonk, NY, USA). The level of statistical significance
was set at 0.05, and all statistical tests were two-sided.
Results
Patient characteristics
The characteristics of the study population are shown in
Table 1. Except for more impaired cardiopulmonary func-
tion according to the New York Heart Association (NYHA)
classification system and higher troponin I levels in patients
with IRD, there were no statistically significant differences
in the severity of CVD, traditional cardiovascular risk
factors, CAD duration, and demographic data between
the two groups. There was a statistically nonsignificant
tendency toward a higher occurrence of previous myo-
cardial infarction (MI) in the IRD group. The use of
studied medications was similar, except for substantially
more frequent use of glucocorticosteroids (median dose
5 mg/day), nonsteroidal anti-inflammatory drugs (NSAIDs),
and disease-modifying antirheumatic drugs (DMARDs) in
the IRD group. As expected, the IRD group also had higher
levels of C-reactive protein (CRP) and erythrocyte sedimen-
tation rate (ESR).
There was no clinical suspicion of current cardiac in-
flammation in any of the patients at the time of CABG
surgery. However, one non-IRD patient had clinical symp-
toms of perimyocarditis 3 months prior to surgery. During
surgery, by gross inspection of the heart, an adherent
pericardium was observed in one patient with RA. This
patient had not had any previous clinical signs of peri-
carditis. In addition, one patient with undifferentiated
connective tissue disease had clinical signs of pericardi-
tis 9 years prior to surgery, and one GCA patient had
clinical signs of myocarditis 14 years prior to surgery.
Cardiac ICIs
The occurrence of ICIs in the right atrium was high
(Table 2). The ICIs were found predominantly in the
epicardium and occurred in 27 (56 %) patients with IRD
and 24 (60 %) non-IRD patients. The occurrence and ex-
tent of the epicardial ICIs were similar in patients with
IRD and non-IRD patients (Fig. 1a, b and c).
Of the four patients with ICIs in the myocardium (one
patient each in the PMR, GCA, SLE, and non-IRD groups),
three patients (SLE, PMR, and non-IRD) had infiltrates lo-
cated in both the epicardium and the myocardium. The
one patient (with RA) with infiltrates in the endocardium
also had infiltrates in the epicardium, but not in the myo-
cardium. There were no significant differences in scores
for the size and number of the epicardial, myocardial, and
endocardial ICIs between patients with IRD and non-IRD
patients (Tables 2 and 3).
The ICIs in all three cardiac layers consisted mostly of
lymphocytes, and they occurred predominantly around
small vessels (Fig. 1d and e). In the epicardium, perivascu-
lar ICIs occurred in 26 (87 %) patients with IRD and in 22
(85 %) non-IRD patients (p = 0.86). No certain signs of
vasculitis were observed in any of the layers in any patient.
We analyzed the relationship between the occurrence
of epicardial ICIs and all patient characteristics shown in
Table 1. Of these, only age was negatively related to the
occurrence of epicardial ICIs in univariate analyses. The
mean age of the patients who had epicardial ICIs was
63.7 ± 11.0 years, and the mean age of those who did not
was 70.6 ± 7.8 years (p = 0.001). When adjusted for age
and sex in multivariate analyses, NYHA class (OR 2.4,
95 % CI 1.1–5.3, p = 0.024) and CAD duration (OR 1.1,
95 % CI 1.0–1.2, p = 0.011) significantly increased the
odds for the occurrence of ICIs in the epicardial layer.
ICIs in one or more of the atrial layers were observed
in 8 (44 %) of 18 patients with RA, 5 (56 %) of 9 patients
with PMR, 5 (63 %) of 8 patients with PSA, and 1 (33 %)
of 3 patients with GCA, as well as in all the patients
with AS (n = 5), SLE (n = 3), and Reiter’s syndrome (n = 1).
In other words, the cardiac ICIs were observed in all of
the IRD diagnostic subgroups except for undifferentiated
connective tissue disease (n = 1). There was no significant
difference in the occurrence of ICIs between the IRD diag-
noses (p = 0.240). We further grouped the patients with
IRD into four larger groups (RA vs. spondylarthropa-
thies vs. GCA/PMR vs. systemic connective tissue dis-
ease), but no significant difference between these
groups was observed regarding the cardiac findings.
Among patients with RA, PSA, or undifferentiated
arthritis, epicardial ICIs were observed in 3 (50 %) of 6
patients treated with methotrexate, in the 1 patient
(100 %) treated with tumor necrosis factor-α inhibitors
in combination with methotrexate, in 3 (100 %) of 3 pa-
tients treated with sulfasalazine, in the 1 patient (100 %)
treated with hydroxychloroquine, and in 16 (55 %) of 29
patients not currently receiving DMARDs. No epicardial
ICIs were observed in patients treated with sulfasalazine
in combination with hydroxychloroquine (n = 1),
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leflunomide (n = 1), azathioprine (n = 1), or CPH-82 (n =
1) (p = 0.145). There was no relationship between cardiac
ICIs and number of DMARDs used previously.
ICIs in skeletal muscle and their relationship to cardiac ICIs
In skeletal muscle, the ICIs occurred in only 1 (5 %) pa-
tient (who had RA) of the 20 patients with IRD and 2
(7 %) of the 28 non-IRD patients. In the one RA patient,
the ICIs (two ICIs per section) were localized around
small vessels. Of the non-IRD patients, one had perivas-
cular ICIs (one ICI per section), while the other had ICIs
in both perivascular and interstitial tissue (more than
three ICIs per section).
No certain signs of vasculitis were observed in the
skeletal muscle in any patient. There were no significant
relationships between the occurrence of ICIs in the rec-
tus abdominis muscle and heart (as well as myocardium)
in the same patients.
Table 1 Patient characteristics
Characteristics IRD (n = 48) Non-IRD (n = 40) p Value
Age, years, mean ± SD 66 ± 10 66 ± 11 0.85
Male sex, n (%) 28 (58) 27 (68) 0.45
Duration of CAD, months, median (IQR) 24 (81) 32 (119) 0.39
History of myocardial infarction, n (%) 30 (63) 19 (48) 0.17
Number of myocardial infarctions, mean ± SD 0.8 ± 0.9 0.6 ± 0.8 0.28
NYHA class, mean ± SD 2.9 ± 0.7 2.6 ± 0.6 0.04
Number of coronary arteries with significant stenosis, mean ± SD 2.7 ± 0.6 2.6 ± 0.7 0.44
Acute coronary syndrome, n (%) 12 (25) 10 (25) 0.90
Left ventricular ejection fraction, mean ± SD 64 ± 12 65 ± 11 0.52
Previous heart surgery, n (%) 1 (2.1) 0 (0) 0.73
Positive family history of CAD,a n (%) 33 (69) 31 (78) 0.41
C-reactive protein, mg/L, median (IQR) 4.9 (10.5) 2.1 (2.6) <0.001
ESR, mm/h, median (IQR) 23 (28) 13 (17) 0.003
Troponin I, ng/ml, median (IQR) 0.06 (0.11) 0.01 (0.04) 0.01
Body mass index, kg/m2, mean ± SD 25 ± 4 26 ± 3 0.58
Hypertension, n (%) 28 (58) 20 (50) 0.46
Current smoker, n (%) 13 (27) 7 (18) 0.26
Previous smoking, n (%) 18 (38) 18 (45) 0.45
Diabetes mellitus, n (%) 6 (13) 5 (13) 0.87
Hypercholesterolemia, n (%) 40 (83) 36 (90) 0.45
Acetylsalicylic acid, n (%) 43 (90) 35 (88) 0.88
ACE inhibitors, n (%) 15 (31) 12 (30) 0.91
Statins, n (%) 37 (77) 32 (80) 0.70
Beta blockers, n (%) 36 (75) 31 (78) 0.71
Disease-modifying antirheumatic drugs,b n (%) 16 (33) 0 (0) <0.001
Systemic glucocorticosteroids, n (%) 19 (40) 0 (0) <0.001
Nonsteroidal anti-inflammatory drugs, n (%) 6 (13) 0 (0) 0.018
Cyclooxygenase 2 selective inhibitors, n (%) 8 (17) 0 (0) 0.004
Duration of IRD, years, mean ± SD 17 ± 12 NA NA
Patient’s global assessment of disease activity,c mean ± SD 3.1 ± 2.5 NA NA
Physician’s global assessment of disease activity,c mean ± SD 1.4 ± 1.3 NA NA
Abbreviations: NA Not applicable, CAD coronary artery disease, IRD inflammatory rheumatic disease, NYHA New York Heart Association, ESR erythrocyte
sedimentation rate, ACE angiotensin-converting enzyme, IQR interquartile range
Owing to missing data for some variables, numbers may not add up to the expected total
aCAD in first-degree relatives younger than age 65 years
bMethotrexate (n = 6), sulfasalazine (n = 4), hydroxychloroquine (n = 1), azathioprine (n = 1), leflunomide (n = 1), etanercept and methotrexate (n = 1),
podofyllotoxine derivatives (CPH-82) (n = 1), hydroxychloroquine and sulfasalazine (n = 1)
cOn a 10-cm visual analogue scale
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Cardiac collagen
Patients with IRD had a higher amount of collagen in the
myocardial layer than non-IRD patients (Fig. 1g, h, j, k
and l). However, no significant difference was observed
between the two groups when it came to the amount of
collagen in the epicardial and endocardial layers (Table 4).
Cardiac adipose tissue
In the epicardial layer, over 70 % of the patients had a
moderate to pronounced amount of adipose tissue (Fig. 1f
and i). There was no significant difference between the two
groups. No adipose tissue was observed in the myocardium
or the endocardium (Table 5). There was no relationship
between the amount of epicardial adipose tissue and epi-
cardial ICIs, body mass index, and inflammatory markers
in serum (CRP, pentraxin 3, and ESR). Nor was there a re-
lationship between the amount of epicardial adipose tissue
and the amount of collagen in the myocardium.
Discussion
In this novel study, we observed a relatively high occur-
rence of inflammation in terms of ICIs in cardiac speci-
mens taken from the right atrium of patients with CAD.
Although ICIs occurred in all three layers, most of them
were located in the epicardium (the visceral layer of the
pericardium), including its adipose tissue. Furthermore,
while multiple and large infiltrates occurred in the epicar-
dium, the endo- and myocardial infiltrates were only small
and single. There was no statistically significant difference
between the IRD and non-IRD groups in the occurrence
and extent of ICIs in any of the cardiac layers.
The cause and clinical relevance of the observed ICIs
are not known. In theory, the observed ICIs may be
independent of CVD or secondary to CVD or its trig-
gers. However, the inflammation might also play a
pathogenic role in the development of cardiovascular
manifestations. One could speculate that the cardiac in-
flammation might be driven by pathogens, autoimmunity,
toxins, ischemia, excessive secretion of proinflammatory
molecules at the systemic or tissue level, and/or downreg-
ulation of processes that terminate inflammatory
reactions.
Although our findings indicate that CAD is frequently
associated with epicardial inflammation, it is still unknown
if these inflammatory changes really are independently re-
lated to CAD. It might be that mild inflammatory changes
in the heart are common and without clinical significance,
in contrast to profound changes that may cause significant
clinical symptomatology. However, we do not know where
the cutoff between “normality” and “pathology” is situated.
Furthermore, it is possible that even mild subclinical
cardiac inflammation might have an adverse impact on
patients’ long-term prognosis, such as by promoting is-
chemia and cardiac remodeling. Interestingly, the patients
who had epicardial ICIs were, on average, seven years
younger at the time of CABG surgery than those with-
out ICIs, possibly indicating that these patients have a
more aggressive form of CVD (requiring CABG at a
younger age) and that this variant of CVD could be more
strongly related to inflammation (including epicardial
inflammation).
Lymphocytic infiltration of the myocardium may be a
sign of myocarditis. However, in our study, myocardial
ICIs were observed in only 4.5 % of patients with CAD.
There was a tendency toward a higher frequency of
myocardial ICIs in the IRD than in the non-IRD group,
but the difference was not statistically significant.
There are indications that myocardial inflammation
might be a frequent phenomenon in autoimmune diseases
[6, 7]. In a population of patients with autoimmune dis-
eases with cardiac symptoms, 90 % of patients had
myocarditis as diagnosed by magnetic resonance imaging
(MRI), and endomyocardial biopsies confirmed the diag-
nosis in 50 % of patients [6]. In keeping with our results,
the myocarditis diagnosis was commonly unrecognized
before the study.
The discrepancy in the results between our present
study and the aforementioned study might be based on
the fact that our patients were examined using only one
section taken from a small cardiac biopsy, while the other
researchers examined the whole heart of their patients by
MRI and using multiple cardiac biopsies [6]. Further-
more, we examined only the right atrium, while their
results indicated that the myocardial inflammation was
probably most pronounced in other cardiac areas. Fur-
ther studies examining the occurrence and cause of
myocardial inflammation in CAD and IRD, and their
Table 2 The number of inflammatory cell infiltrates in the three
cardiac layers, per section
IRD (n = 48) Non-IRD (n = 40) p Value
Epicardium
No infiltrates 21 (44) 16 (40) 0.30
One infiltrate 14 (29) 7 (18)
Two or three infiltrates 11 (23) 13 (33)
More than three infiltrates 2 (4) 4 (10)
Myocardium
No infiltrates 45 (94) 39 (98) 0.47
One infiltrate 3 (6) 1 (3)
More than one infiltrate 0 (0) 0 (0)
Endocardium
No infiltrates 47 (98) 40 (100) 0.73
One infiltrate 1 (2) 0 (0)
More than one infiltrate 0 (0) 0 (0)
IRD Inflammatory rheumatic disease
Values are the number (percentage) of patients
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potential roles in the development of heart failure, are
therefore needed.
Patients with IRD had more collagen, one of the key
proteins of the ECM, in their myocardium (but not in
their endo- and epicardium) than non-IRD patients. In
the heart, the ECM provides structural support for the
cardiomyocytes and vessels, and it secures tissue integ-
rity and cardiac pumping function [10, 15]. Increased
Fig. 1 Histological evaluation of right atrium specimens by light microscopy. a A large inflammatory cell infiltrate (ICI) in the epicardium of a
patient with rheumatoid arthritis (RA) (hematoxylin and eosin stain, original magnification × 100). b A large ICI in the epicardium of a patient with
ankylosing spondylitis (hematoxylin and eosin stain, original magnification × 400). c A smaller ICI in the myocardium of a patient with systemic
lupus erythematosus (hematoxylin and eosin stain, original magnification × 400). d and e Perivascular ICIs in the epicardium of patients with RA
(hematoxylin and eosin stain, original magnification × 400). f A smaller ICI located adjacent to adipose cells in the epicardium of a patient with
non-inflammatory rheumatic disease (non-IRD) (hematoxylin and eosin stain, original magnification × 400). g Multifocal, moderately increased
collagen in the epicardium of a patient with RA (Lendrum-Martius yellow, scarlet, and blue [MSB] stain, original magnification × 100). h Focally
pronounced amounts of collagen in the epicardium of a non-IRD patient (Lendrum-MSB stain, original magnification × 100). i Pronounced amounts of
adipose tissue in the epicardium of a non-IRD patient (Lendrum-MSB stain, original magnification × 100). j Normal amounts of collagen in the
myocardium of a patient with RA (Lendrum-MSB stain, original magnification × 100). k and l Diffusely pronounced amount of collagen in the myocardium
of a patient with polymyalgia rheumatica (k Lendrum-MSB stain, original magnification × 100; l Lendrum-MSB stain, original magnification × 400)
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content of cardiac collagen leads to mechanical stiffness,
as well as disruption of the electronic connectivity be-
tween cardiomyocytes, resulting in diastolic and systolic
dysfunction [16].
In the cardiac interstitium, the fibroblast is the main cell
type and producer of ECM proteins [17]. When an injury
to the myocardium occurs due to, for example, ischemia
and mechanical stress, the fibroblasts may initiate an
inflammatory reaction by acquiring a proinflammatory
phenotype characterized by increased cytokine expres-
sion and collagen synthesis [18].
Thus, the increased amount of myocardial collagen in
patients with IRD might be due to increased activation
of the fibroblasts due to various reasons, such as increased
systemic or local proinflammatory stimuli (including
subclinical myocarditis). In keeping with this hypothesis,
low-grade inflammation has been shown to be one of the
triggers of ECM remodeling [19].
Our results stand in apparent contrast to this notion,
as we did not find any relationship between ICIs and
collagen in the myocardium. However, actual collagen pro-
duction is likely to be induced by a preceding (and not ne-
cessarily the current) inflammatory process. Furthermore,
in spite of our findings, we cannot rule out the influence of
ongoing low-grade inflammation in the myocardium, as
observed in our previous study. In that study, we observed
high occurrence of sporadic immune cells and expression
of proinflammatory cytokines, human leukocyte antigen,
and adhesion molecules in the myocardium of patients
with CAD, with more pronounced myocardial inflam-
mation and microvascular impairment in patients with
IRD than in non-IRD patients [7]. In both these studies,
we used the same type of atrial biopsies, but from different
subgroups of the same patient cohort (with a greater
patient population in the present study). As opposed to
the previous study, where we used immunohistochemi-
cal methods to examine snap-frozen biopsies, in the
present study we examined formalin-fixed specimens
by histochemistry and looked for ICIs and not sporadic
immune cells. Thus, it appears that subtle inflammatory
changes (expression of proinflammatory molecules and
presence of sporadic cells) in the myocardium of pa-
tients with CAD, in particular those with IRD, occur at
Table 4 The amount of collagen in the cardiac layers, per section
IRD (n = 48) Non-IRD (n = 40) p Value
Epicardium
Little 15 (60) 12 (50) 0.40
Moderate 10 (40) 10 (42)
Pronounced 0 (0) 2 (8)
Myocardium
Little 25 (58) 32 (80) 0.04
Moderate 17 (40) 8 (20)
Pronounced 1 (2) 0 (0)
Endocardium
Little 21 (60) 19 (63) 0.60
Moderate 12 (34) 11 (37)
Pronounced 2 (6) 0 (0)
IRD Inflammatory rheumatic disease
Values are the number (percentage) of patients. Owing to missing data for
some variables, numbers may not add up to the expected total
Table 5 The amount of adipose tissue in the cardiac layers,
per section
IRD (n = 48) Non-IRD (n = 40) p Value
Epicardium
None 3 (12) 1 (4) 0.55
Little 3 (12) 6 (25)
Moderate 16 (64) 2 (63)
Pronounced 3 (12) 2 (8)
Myocardium
None 42 (98) 40 (100) 1.00
Little 1 (2) 0 (0)
Moderate and pronounced 0 (0) 0 (0)
Endocardium
None 26 (74) 25 (83) 0.38
Little 9 (26) 5 (17)
Moderate and pronounced 0 (0) 0 (0)
IRD Inflammatory rheumatic disease
Values are the number (percentage) of patients. Owing to missing data for
some variables, numbers may not add up to the expected total
Table 3 The size of the largest inflammatory cell infiltrates in
the three cardiac layers, per section
IRD (n = 48) Non-IRD (n = 40) p Value
Epicardium
No mononuclear cells 21 (44) 16 (40) 0.63
< 50 mononuclear cells 16 (33) 12 (30)
50–99 mononuclear cells 4 (8) 7 (18)
100–199 mononuclear cells 7 (15) 4 (10)
≥ 200 mononuclear cells 0 (0) 1 (3)
Myocardium
No mononuclear cells 45 (94) 39 (98) 0.47
< 50 mononuclear cells 3 (6) 1 (3)
≥ 50 mononuclear cells 0 (0) 0 (0)
Endocardium
No mononuclear cells 47 (98) 40 (100) 0.73
< 50 mononuclear cells 1 (2) 0 (0)
≥ 50 mononuclear cells 0 (0) 0 (0)
IRD Inflammatory rheumatic disease
Values are the number (percentage) of patients
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a high frequency, while more robust changes, in terms
of ICIs, are less common.
Although a previous mouse study revealed that senes-
cent cardiac fibroblasts markedly accumulated in the heart
after MI [20], there was no association between amount of
collagen and previous MIs in our present study. Neverthe-
less, because patients with IRD have an increased risk of
silent MI than the general population [21], we cannot def-
initely rule out a pathogenic role of ischemia in the exag-
gerated collagen production in the myocardium of
patients with IRD. Furthermore, it is possible that not only
acute but also chronic ischemia might contribute to in-
creased collagen production.
Pericarditis is a relatively common manifestation of
IRD, and it may affect both the parietal and visceral parts
of the pericardium [1, 22–24]. Clinical manifestations of
pericarditis in patients with RA, however, occur with
much lower frequency [1, 22]. Thus, pericarditis in RA
has been considered to be mostly without clinical import-
ance. As coronary arteries pass through the epicardium, it
is possible that pathological changes in this area might
negatively influence their nutrition, morphology, and flow
(e.g., due to the compression or impaired compliance of
coronary arteries). One may speculate that the epicardial
pathologies may contribute to the development of coron-
ary atherosclerosis and even plaque instability. This could
be due to the spread of the inflammatory process into the
adventitia of coronary arteries, and from there further on
toward their luminal parts. Hence, it is possible that even
apparently subclinical pericarditis might promote the de-
velopment of premature CVD in IRD.
Most of the observed epicardial ICIs and all of the ICIs
in the myo- and endocardium were localized around
small vessels. Hypothetically, the observed perivascular
inflammation might be part of a generalized small vessel
impairment in IRD, involved in the development of both
IRD-specific and cardiovascular manifestations [5]. Even
though perivascular inflammation is considered to have
much less clinical impact than vasculitis, it might never-
theless influence vascular morphology and function. This
area therefore warrants further study.
Previous autopsy studies indicated a relatively high oc-
currence of cardiac vasculitis in some IRDs, such as RA
[1, 25]. However, we did not observe any clear signs of vascu-
litis in any cardiac layer. The discrepancy between our and
previous findings may be due to different examined tissue
sizes, different locations of tissue sampling, and use of differ-
ent histological criteria for diagnosing vasculitis. Further-
more, most of the examined patients with IRD in our study
had low to moderate disease activity. Thus, we cannot ex-
clude the possibility that small vessel vasculitis occurs more
frequently in patients with IRD with high disease activity.
There is emerging evidence suggesting a link between
the volume of adipose tissue in the epicardium and the
perivascular tissue related to the cardiovascular system
and CAD [5, 26, 27]. It is possible that the adipose tissue
in the cardiovascular system increases cardiovascular risk
because of its mechanical, metabolic, endocrinologic, and
paracrine properties.
It has been proposed that the premature CVD in IRD
might be related to increased amounts of adipose tissue
in the cardiovascular system. IRD has been reported to
be associated with increased risk of visceral obesity and
with increased volume of epicardial and perivascular adi-
pose tissue [28, 29]. However, in our biopsies, we did
not observe any difference in the amount of epicardial
adipose tissue between patients with IRD and non-IRD
patients. Nevertheless, the potential role of the increased
volume of adipose tissue in the premature atherogenesis
in IRD cannot be definitely ruled out, because we exam-
ined only small biopsies and not the total mass of epicar-
dial adipose tissue in a relatively small sample of patients.
Also, it is possible that both groups have similar amounts
of epicardial adipose tissue because both groups are at
similar stages of CVD in terms of their need for CABG.
Furthermore, it is important to keep in mind that not only
the volume but also the function of adipose cells may be
important.
Epicardial adipose tissue in patients with CAD has
been shown to have increased cytokine expression at the
tissue level without evidence of increased proinflamma-
tory cytokines in serum [30]. In keeping with these re-
sults, we did not observe any significant relationship
between epicardial adipose tissue and serological inflam-
matory markers.
Our results could have been influenced by the fact that
the majority of patients with IRD had a long-standing
rheumatic disease duration (mean 17 years) and were in
clinical remission at the time of CABG surgery. It is
known that DMARDs could have an effect on vascular
and cardiac inflammation [31, 32], and the antirheumatic
treatment might result not only in the improvement of
the IRD-specific manifestation and systemic inflammation
but also in reduction of inflammation in the cardiovascu-
lar system. It is possible that certain DMARDs could have
a better effect on cardiac inflammation than others. There
is therefore a need for further studies on this topic. How-
ever, we observed no relationship between the use of
DMARDs and the presence of cardiac ICIs or between
cardiac ICIs and markers of systemic inflammation, such
as CRP and ESR.
Our study has several possible limitations. First, owing
to the cross-sectional design of our study, inferences on
the direction of causality cannot be drawn. Second,
owing to a relatively small sample size, the apparent lack
of some differences and associations may be false as a
result of type II errors. Still, this is, to our knowledge,
the largest study comparing surgical specimens from the
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heart in matched patients with CAD with versus without
IRD. The exclusivity of the tissue samples should be ap-
preciated, as it is extremely challenging to obtain surgi-
cal cardiac specimens, especially from patients with rare
diseases. Fresh surgical specimens have advantages over
autopsy specimens, which may be deteriorated by post-
mortem processes. The novel findings in our present
study confer important insights into cardiac biology and
justify further research in this field. Third, an additional
disadvantage of our study is the heterogeneity of the
IRD group. However, the study design allows for compari-
son of trends in the respective IRD diagnostic subgroups,
though no significant difference between the subgroups
was observed. Indeed, larger studies of vascular inflamma-
tion in different rheumatic diseases are warranted.
One of the strengths of our study was the detailed
clinical and laboratory characterizations of our patient
population, allowing for a comprehensive evaluation of
the patients.
Conclusions
ICIs in the heart of patients with CAD occur at a high
frequency, predominantly in the epicardial layer. Even
though perivascular inflammation was frequent, vasculitis
occurred in none of the patients. On one hand, because
patients with IRD and non-IRD patients had a similar bur-
den of ICIs in all three cardiac layers, our results do not
support the notion that inflammation in the cardiac peri-,
epi-, and myocardium plays a more important role in the
pathogenesis of CVD in patients with IRD than in non-
IRD patients. On the other hand, its role cannot be defini-
tively ruled out, owing to the cross-sectional design of our
study and the small size of the examined samples, which
were collected from the right atrium only. The increased
amount of collagen in the myocardium of patients with
IRD suggests differences in the ECM, possibly in response
to ischemia or due to immunologic mechanisms enhan-
cing collagen production by fibroblasts, which might play
a role in cardiac remodeling and which might be a target
for novel therapies for heart failure. Of note, the negative
relationship between age and the occurrence of epicardial
ICIs may indicate that CAD requiring early CABG is more
strongly related to epicardial inflammation than that re-
quiring CABG in older patients.
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